Sarepta to Take Brookline Bancorp's Place in S&P 600 Starting September 2nd

Written by Emily J. Thompson, Senior Investment Analyst

SRPT+0.28%

Updated: Sep 02 2025

0mins

Acquisition Announcement: Berkshire Hills Bancorp (BHLB) is set to acquire Brookline Bancorp (BRKL), with the deal nearing completion subject to final conditions.
Post-Merger Changes: After the merger, Berkshire Hills Bancorp will be renamed Beacon Financial (BBT) and will continue to be listed in the S&P SmallCap 600.

SRPT

$21.85+Infinity%1D

Analyst Views on SRPT

Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 20.80 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Analyst Rating

4 Buy

10 Hold

4 Sell

Hold

Current: 21.790

Low

5.00

Averages

20.80

High

45.00

Current: 21.790

Low

5.00

Averages

20.80

High

45.00

Guggenheim

NULL -> Buy

upgrade

$90 -> $140

2026-01-20

New

Reason

Guggenheim

Price Target

$90 -> $140

AI Analysis

2026-01-20

New

upgrade

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Structure Therapeutics to $140 from $90 and keeps a Buy rating on the shares. The firm is updating its model to reflect increased confidence in aleniglipron's ultimate Phase 3 and commercial success after "a strong December" that featured "robust" topline ACCESS Phase 2b data, the Phase 1 start of oral amylin ACCG-2671, and the company being well financed for Phase 3, the analyst tells investors.

Citizens

Outperform

maintain

$87 -> $120

2025-12-12

Reason

Citizens

Price Target

$87 -> $120

2025-12-12

maintain

Outperform

Reason

Citizens raised the firm's price target on Structure Therapeutics to $120 from $87 and keeps an Outperform rating on the shares. The Phase 2b data for aleniglipron fundamentally derisk the small molecule GLP agonist, and the firm is not losing the forest through the trees, the analyst tells investors in a research note. There could be ongoing debate on aleniglipron's tolerability, but there is solid evidence to support an improved Phase 3 profile, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRPT

Unlock Now

Wedbush

NULL -> Outperform

initiated

$32

2025-12-09

Reason

Wedbush

Price Target

$32

2025-12-09

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Sarepta with an Outperform rating and $32 price target.

Wedbush

Outperform

initiated

$32

2025-12-09

Reason

Wedbush

Price Target

$32

2025-12-09

initiated

Outperform

Reason

As previously reported, Wedbush initiated coverage of Sarepta with an Outperform rating and $32 price target. The firm sees the early summer selloff due to Elevidys patient deaths as overdone, and even after the subsequent recovery following the Food and Drug Administration's quick reversal for Elevidys to remain available to ambulatory patients, Wedbush sees further upside from potential re-approval in non-ambulatory patients as well. On exon-skipping products that have stably generated close to $1B in annual sales, despite the recent negative ESSENCE study data and emerging competition, the firm projects continued patient uptake based on a high compliance rate that Sarepta has reported, comprehensive real world data supporting clinical benefit, and favorable key opinion leader feedback.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.